aprepitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
netupitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
Palonosetron (0 RCTs; 0 participants) · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
aprepitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
azasetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
aprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
casopitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
Participant‐reported pain intensity VAS (0‐10, lower score = less pain) · people with moderate to severe cancer pain
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – nausea compared with morphine (very low certainty).
1 finding from 1 review
Vomiting · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – vomiting compared with morphine (very low certainty).
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – dizziness compared with morphine (very low certainty).
1 finding from 1 review
Constipation · people with moderate to severe cancer pain
1 finding from 1 review
Quality of life · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with moderate to severe cancer pain
1 finding from 1 review
Relief of pain · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review